CD3+, CD4+ and CD8+ T-cells are being described along with the presence of CD68+ macrophages, the presence of MHC class I antigens (HLA-A, B and C), the presence of HLA-DR, the expression of tumor-associated antigens (e.g. NY-ESO-1, mesothelin or survivin) to test for T-cell responses directed against non-mutant target antigens, as well as molecules associated with immune-suppression/evasion (e.g. PD-1, PDL-1 and CD47) along with the description if immune cells reside within the tumor or rather around, as single cells, or in clusters (Figure 8). The gene discussed is HLA-A; the disease is neoplasm.